Sanofi's Amcenestrant Combo Therapy Shows ORR of 34% In Breast Cancer Patients

Sanofi SA SNY revealed a new early peek at data from breast cancer candidate amcenestrant, an oral selective estrogen receptor degrader.
Data will be presented at the 2021 American Society of Clinical Oncology Annual Meeting.
In pooled data from the phase 1 AMEERA-1 trial, made up of 35 patients, its drug amcenestrant hit an objective response rate (ORR) of 34% and a clinical benefit rate (CBR) of 74% when combined with Pfizer Inc’s PFE Ibrance (palbociclib).
The data come from a series of post-menopausal women with ER+/HER2- metastatic breast cancer (MBC) who were pretreated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.
The trial also saw a “favorable overall safety profile” with no “clinically significant cardiac or ocular safety findings,” which has hit other drugs in this class.
For all grade events, amcenestrant treatment-related adverse events occurred in 72% and to palbociclib in 90% of patients, and for severe/life-threatening in 15% and 46% of patients, respectively.
Price Action: SNY shares are up 2.3% at $54.07 during the market session on the last check Thursday.